Cyclo Therapeutics Inc.

2.10-0.1000-4.55%Vol 25.77K1Y Perf -79.72%
Jun 24th, 2022 16:00 DELAYED
BID2.04 ASK2.70
Open2.10 Previous Close2.20
Pre-Market- After-Market-
 - -  - -%
Target Price
10.00 
Analyst Rating
Strong Buy 1.00
Potential %
376.19 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★     50.60
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★★     59.49
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
2.37 
Earnings Rating
Market Cap17.67M 
Earnings Date
16th Aug 2022
Alpha-0.02 Standard Deviation0.20
Beta0.49 

Today's Price Range

2.102.28

52W Range

1.8811.15

5 Year PE Ratio Range

-5.00-2.70

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-6.25%
1 Month
5.00%
3 Months
-26.32%
6 Months
-46.56%
1 Year
-79.72%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
CYTH2.10-0.1000-4.55
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
4.20
5.50
0.00
0.00
-
Leverage Ratio 1.30
ProfitabilityValueIndustryS&P 500US Markets
90.30
-925.50
-924.20
-589.10
-
RevenueValueIndustryS&P 500US Markets
1.42M
0.17
12.94
-0.07
Earnings HistoryEstimateReportedSurprise %
Q01 2022--0.33-
Q03 2021--0.60-
Q02 2021--0.56-
Q01 2021--0.76-
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date16th Aug 2022
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume25.77K
Shares Outstanding8.42K
Shares Float7.65M
Trades Count203
Dollar Volume55.18K
Avg. Volume20.58K
Avg. Weekly Volume10.52K
Avg. Monthly Volume16.75K
Avg. Quarterly Volume34.47K

Cyclo Therapeutics Inc. (NASDAQ: CYTH) stock closed at 2.1 per share at the end of the most recent trading day (a -4.55% change compared to the prior day closing price) with a volume of 25.77K shares and market capitalization of 17.67M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 8 people. Cyclo Therapeutics Inc. CEO is N. Scott Fine.

The one-year performance of Cyclo Therapeutics Inc. stock is -79.72%, while year-to-date (YTD) performance is -43.7%. CYTH stock has a five-year performance of %. Its 52-week range is between 1.88 and 11.15, which gives CYTH stock a 52-week price range ratio of 2.37%

Cyclo Therapeutics Inc. currently has a PE ratio of -1.20, a price-to-book (PB) ratio of 1.44, a price-to-sale (PS) ratio of 13.25, a price to cashflow ratio of 63.20, a PEG ratio of 2.32, a ROA of -76.45%, a ROC of -94.83% and a ROE of -95.15%. The company’s profit margin is -%, its EBITDA margin is -924.20%, and its revenue ttm is $1.42 Million , which makes it $0.17 revenue per share.

Of the last four earnings reports from Cyclo Therapeutics Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Cyclo Therapeutics Inc.’s next earnings report date is 16th Aug 2022.

The consensus rating of Wall Street analysts for Cyclo Therapeutics Inc. is Strong Buy (1), with a target price of $10, which is +376.19% compared to the current price. The earnings rating for Cyclo Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cyclo Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Cyclo Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 6.86, ATR14 : 0.18, CCI20 : -41.49, Chaikin Money Flow : -0.08, MACD : -0.04, Money Flow Index : 43.43, ROC : -4.55, RSI : 43.85, STOCH (14,3) : 21.28, STOCH RSI : 0.06, UO : 45.55, Williams %R : -78.72), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cyclo Therapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (100.00 %)
1 (100.00 %)
0
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0
Hold
0 (0.00 %)
0 (0.00 %)
0
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0
Strong Sell
0 (0.00 %)
0 (0.00 %)
0
Summary RatingStrong Buy
1.00
Strong Buy
1.00
-
0.00

Cyclo Therapeutics Inc.

Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company develops cyclodextrin-based products for the treatment of disease. Its lead drug candidate, Trappsol Cyclo, treats Niemann-Pick Type C disease (NPC). Its other products include Trappsol HPB, Trappsol Fine Chemical, and Aquaplex.

CEO: N. Scott Fine

Telephone: +1 386 418-8060

Address: 6714 NW 16th Street, Gainesville 32653, FL, US

Number of employees: 8

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

42%58%

Bearish Bullish

50%50%

Bearish Bullish

52%48%

News

Stocktwits